Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial.

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

Proinsulin-transferrin (ProINS-Tf) fusion protein was evaluated for its in vivo pharmacokinetics, efficacy, and mechanism. Our previous studies have shown that ProINS-Tf was converted to active ...

PORTLAND, HI, UNITED STATES, September 17, 2024 /EINPresswire / -- The global protein therapeutics <a target=_blank href= ...

IBI363 has earned fast track designation from the FDA for the treatment of previously treated unresectable advanced melanoma.

Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows: Effect of nomlabofusp administration on ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Because the aim of the experiment is to compare GST with a GST fusion protein, it is necessary to prepare enough precleared lysate for each reaction. Efficient mixing of reagents is the key to ...

We demonstrate a method for purification of soluble fusion proteins incorporating an ELP tag. Advantages of this method, termed "inverse transition cycling," include technical simplicity ...

Moreover, the application of fluctuating forces to the vesicle membrane facilitated homotypic fusion even in large vesicles.

Lonza’s GS Gene Expression System® is a comprehensive toolbox for therapeutic protein expression, supporting the production ...